Literature DB >> 22043941

Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis.

Felix Lu1, Jason Lamontagne, Angela Sun, Mark Pinkerton, Timothy Block, Xuanyong Lu.   

Abstract

Serine protease inhibitor Kazal (SPIK) is an inflammatory protein whose levels are elevated in numerous cancers. However, the role of this protein in cancer development is unknown. We have recently found that SPIK suppresses serine protease-dependent cell apoptosis. Here, we report that anti-SPIK antibodies can co-immmunoprecipitate serine protease granzyme A (GzmA), a cytolytic granule secreted by cytotoxic T lymphocytes and natural killer cells during immune surveillance, and that SPIK suppresses GzmA-induced cell apoptosis. Deletion studies show that the C3-C4 region of SPIK is critical for this suppression. These studies suggest that over-expression of SPIK may prevent GzmA-mediated immune-killing, thereby establishing the tolerance of cancer cells to the body's immune surveillance system. Suppression of over-expressed SPIK can restore the susceptibility of these cells to apoptotic death triggered by GzmA. This finding implies that it is possible to overcome tolerance of cancer cells to the body's immune surveillance system and restore the GzmA-mediated immune-killing by suppressing the over-expression of SPIK.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22043941      PMCID: PMC3230794          DOI: 10.1111/j.1365-2567.2011.03498.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis.

Authors:  H Witt; W Luck; H C Hennies; M Classen; A Kage; U Lass; O Landt; M Becker
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

Review 2.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Expression of pancreatic secretory trypsin inhibitor gene in human colorectal tumor.

Authors:  N Tomita; S Doi; M Higashiyama; H Morimoto; M Murotani; Y Kawasaki; T Monden; T Shimano; A Horii; H Yokouchi
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

Review 4.  Nuclear war: the granzyme A-bomb.

Authors:  Judy Lieberman; Zusen Fan
Journal:  Curr Opin Immunol       Date:  2003-10       Impact factor: 7.486

5.  Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection.

Authors:  Akihiko Tonouchi; Masayuki Ohtsuka; Hiroshi Ito; Fumio Kimura; Hiroaki Shimizu; Masaki Kato; Yoshinori Nimura; Katsuro Iwase; Takaki Hiwasa; Naohiko Seki; Masaki Takiguchi; Masaru Miyazaki
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

6.  Serum pancreatic secretory trypsin inhibitor (PSTI) in patients with inflammatory diseases.

Authors:  M Ogawa; T Shibata; T Niinobu; K Uda; N Takata; T Mori
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

Review 7.  Tumor-associated trypsin inhibitor.

Authors:  Ulf-Håkan Stenman
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

Review 8.  Apoptosis. Its significance in cancer and cancer therapy.

Authors:  J F Kerr; C M Winterford; B V Harmon
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

Review 9.  Granzymes in cancer and immunity.

Authors:  S P Cullen; M Brunet; S J Martin
Journal:  Cell Death Differ       Date:  2010-01-15       Impact factor: 15.828

10.  Elevation of circulating monitor peptide/pancreatic secretory trypsin inhibitor-I (PSTI-61) after turpentine-induced inflammation in rats: hepatocytes produce it as an acute phase reactant.

Authors:  K Uda; A Murata; J Nishijima; S Doi; N Tomita; M Ogawa; T Mori
Journal:  J Surg Res       Date:  1994-11       Impact factor: 2.192

View more
  5 in total

1.  SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.

Authors:  Danyelle Winchester; Luisel Ricks-Santi; Tshela Mason; Muneer Abbas; Robert L Copeland; Desta Beyene; Emmanuel Y Jingwi; Georgia M Dunston; Yasmine M Kanaan
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

2.  Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma.

Authors:  Felix Lu; Pir Ahmad Shah; Abhishek Rao; Cynthia Gifford-Hollingsworth; Anne Chen; Gary Trey; Mina Soryal; Arslan Talat; Aysha Aslam; Bilal Nasir; Saad Choudhry; Rizwan Ishtiaq; Hanna Sanoff; Lanla F Conteh; Anne Noonan; Ke-Qin Hu; Carl Schmidt; Min Fu; Jesse Civan; Gary Xiao; Daryl T-Y Lau; Xuanyong Lu
Journal:  Clin Transl Gastroenterol       Date:  2020-12       Impact factor: 4.396

3.  Structural and Biophysical Insights into SPINK1 Bound to Human Cationic Trypsin.

Authors:  Felix Nagel; Gottfried J Palm; Norman Geist; Thomas C R McDonnell; Anne Susemihl; Britta Girbardt; Julia Mayerle; Markus M Lerch; Michael Lammers; Mihaela Delcea
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

4.  Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease.

Authors:  Gian Paolo Caviglia; Aurora Nicolosi; Maria Lorena Abate; Patrizia Carucci; Chiara Rosso; Emanuela Rolle; Angelo Armandi; Serena Aneli; Antonella Olivero; Alessandra Risso; Davide Giuseppe Ribaldone; Christian Fermer; Giorgio Maria Saracco; Silvia Gaia; Elisabetta Bugianesi
Journal:  Curr Oncol       Date:  2022-07-31       Impact factor: 3.109

5.  SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.

Authors:  R Tiwari; S K Pandey; S Goel; V Bhatia; S Shukla; X Jing; S M Dhanasekaran; B Ateeq
Journal:  Oncogenesis       Date:  2015-08-10       Impact factor: 7.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.